{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:18:29Z","timestamp":1791850709436,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Epidermal growth factor receptor (EGFR) inhibitors are established therapies for advanced lung, colorectal, and head and neck cancers. They commonly cause acneiform eruptions that affect patient quality of life and may lead to discontinuation of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review and meta\u2010analysis was undertaken to assess strategies for the prevention and reactive management of acneiform rash associated with EGFR inhibitor therapy for advanced lung, colorectal, and head and neck cancers. A systematic Medline, Embase, and EBM Reviews database search was conducted on the 2nd of January 2021. The Preferred Reporting Items for Systematic Reviews and Meta\u2010analyses statement was followed and the studies were critically appraised. Studies were selected if they focused on preventing or treating acneiform eruptions in adults being treated for advanced lung cancer, colorectal cancer, and head and neck cancers with EGFR inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Oral antibiotics had the greatest efficacy in preventing grade 2 or higher acneiform eruptions with a relative risk reduction of 40% (RR\u00a0=\u00a0.6, 95% CI .46\u2013.79, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.01). Other treatment modalities did not have statistically significant results. Topical antibiotics had a total relative risk reduction of 19% (RR\u00a0=\u00a0.81, 95% CI .45\u20131.48, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.5). Vitamin K1 cream did not reduce the relative risk (RR\u00a0=\u00a01.08, 95% CI .45\u20131.48, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.50). Sunscreen had a total relative risk reduction of 25% (RR\u00a0=\u00a0.75, 95% CI .49\u20131.14, <jats:italic>p<\/jats:italic>\u00a0=\u00a0.18).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of this meta\u2010analysis reinforce the fact that oral tetracycline antibiotics are the most efficacious prophylactic option for acneiform eruptions in EGFR inhibitors. They should be offered to suitable patients commencing treatment and used with a general skin\u2010care routine involving emollients and avoidance of irritants.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13740","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:54:12Z","timestamp":1648623252000},"page":"526-539","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"18","author":[{"given":"Mahdieh","family":"Gorji","sequence":"first","affiliation":[{"name":"Westmead Hospital Dermatology Department  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8579-7634","authenticated-orcid":false,"given":"Joseph","family":"Joseph","sequence":"additional","affiliation":[{"name":"Westmead Hospital Dermatology Department  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Northern Clinical School, University of Sydney Royal North Shore Hospital  Sydney New South Wales Australia"},{"name":"Genesis Care North Shore Health Hub  St Leonards New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saxon D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Australian National University Medical School, College of Health and Medicine The Australian National University  Canberra Australian\u00a0Capital Territory Australia"},{"name":"The Dermatology and Skin Cancer Centre  St Leonards New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.648617"},{"issue":"2","key":"e_1_2_11_5_1","first-page":"15","article-title":"Anti\u2010EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers","volume":"20","author":"Vokes EE","year":"2006","journal-title":"Oncology (Williston)"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"issue":"4","key":"e_1_2_11_7_1","first-page":"219","article-title":"The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist","volume":"35","author":"Kloth DD","year":"2010","journal-title":"P T"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000371821"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M241"},{"issue":"1","key":"e_1_2_11_10_1","first-page":"S18","article-title":"Adverse events associated with anti\u2010EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih M","year":"2010","journal-title":"Curr Oncol"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06026.x"},{"issue":"4","key":"e_1_2_11_12_1","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula Y","year":"2010","journal-title":"J Support Oncol."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25090"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.e19049"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6987"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23621"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.046"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0082"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0988-5"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1715-1"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2013.10.001"},{"key":"e_1_2_11_24_1","first-page":"1261","article-title":"Randomized double\u2010blind trial of prophylactic topical Evozac Calming Skin Spray for gefitinib\u2010associated acne\u2010like eruption","volume":"7","author":"Wang Y","year":"2014","journal-title":"Onco Targets Ther"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.03.019"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.251"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0116-x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.019"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3918"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3623-x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21249"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy015"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0156"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0221"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909118819820"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03927-x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4600-8"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000511869"},{"issue":"6","key":"e_1_2_11_39_1","first-page":"933","article-title":"Randomized, double\u2010blind, placebo\u2010controlled phase II study on the efficacy and safety of vitamin K1 ointment for cetuximab or panitumumab\u2010induced acneiform eruptions\u2014VIKTORIA study","volume":"47","author":"Hashimoto H","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18340"},{"key":"e_1_2_11_41_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.National Cancer Institute;2021."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_2_11_43_1","unstructured":"HigginsJPT Savovi\u0107J PageMJ ElbersRG SterneJAC. Chapter 8: Assessing Risk of Bias in a Randomized Trial. Cochrane; 2020. Available from:www.training.cochrane.org\/handbook. Accessed January 2 2021."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13740","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:22:27Z","timestamp":1692649347000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/ajco.13740"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13740","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"2021-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}